The UK’s NICE loses to Big Pharma in a stunning decision:
At issue was the refusal by NICE, the National Institute for Health and Clinical Excellence, to give the companies access to the computer models the cost-effectiveness gurus used in making their determination about the utility of Aricept. The Court of Appeal ruled that was unfair.
This could be the beginning of the end of NICE. Once drug companies know how they make their judgments, they can come up with ways to circumvent and challenge its decisions.
If a comparative effectiveness institute can’t stand up to Big Pharma abroad, there is no way in hell it will happen Stateside.
